Multibagger Selection: Perplexity's picks
Perplexity picked LWLG, SATL, ARTV, KOD, TYGO with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Perplexity |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | LWLG | — | 74% | — | — |
| 2 | SATL | — | 71% | — | — |
| 3 | ARTV | — | 68% | — | — |
| 4 | KOD | — | 65% | — | — |
| 5 | TYGO | — | 62% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +0.23% | -0.42% | 1.28x | 0 |
The model's market view
Small and mid-cap US equities face a mixed backdrop: elevated Treasury yields near 5.2% pressure valuation multiples, but AI infrastructure spending, defense budgets, and biotech innovation create pockets of exceptional growth. The $200M–$5B market cap range offers the best asymmetry for multibagger candidates, with liquidity sufficient for institutional participation. Key themes include electro-optic polymers for AI datacenters, sovereign earth observation, NK cell therapy in autoimmune disease, retina-focused biologics, and geospatial analytics. Balance sheet discipline and credible paths to profitability separate survivors from dilution traps.
Why each pick
LWLG
Thesis: Lightwave Logic's Perkinamine electro-optic polymer platform targets the $54B modulator market for AI datacenters and co-packaged optics. Five Fortune Global 500 customers are in Stage 3 (prototype-to-final-product), with volume production targeted for H2 2027. The company has four foundry partnerships (SilTerra, Global Foundries, two unnamed), with wafer deliveries expected in Q3–Q4 2026. Revenue remains minimal ($32.7K in Q2 2026), but the operating inflection is visible: NRE fees now, licensing and volume production in 2027. With $95.9M in cash and marketable securities as of June 2026 and no debt, the runway extends through 2027. The $821M market cap prices in early commercialization risk but leaves substantial upside if even one Stage 3 customer converts to production. Screens met: 1 (valuation below TAM capture potential), 2 (revenue acceleration from near-zero base, path to FCF), 3 (TAM expansion in AI optics), 6 (wafer deliveries Q3–Q4 2026, Stage 3 conversions), 7 (rising institutional interest in AI supply chain).
SATL
Thesis: Satellogic is a vertically integrated earth observation company with a growing constellation of high-resolution satellites. Q2 2026 revenue surged 259% YoY to $15.9M, driven by Space Systems ($8.8M) and Data & Analytics ($7.1M). The company has $80.7M in contracted backlog and is expanding sovereign defense partnerships (e.g., $12M NewSat agreement). Gross margin is improving (35% in Q2 2026 vs. 25% in Q1), and operating losses are narrowing as scale increases. At $949M market cap, SATL trades at ~15x EV/sales on an annualized $60M+ revenue base, leaving room for 3x–5x upside if growth sustains and margins expand. Screens met: 1 (P/S below industry median for high-growth space tech), 2 (revenue acceleration, margin expansion), 3 (259% YoY growth, $80.7M backlog), 4 (gross margin improving to 35%), 6 (sovereign satellite deliveries, Slingshot program expansion).
ARTV
Thesis: Artiva Biotherapeutics is developing AlloNK, an allogeneic NK cell therapy, for refractory rheumatoid arthritis (RA). The company has FDA alignment on a single Phase 3 registrational trial (150 patients, ACR50 at 6 months) to initiate in H2 2026, with readout expected in 2028. RA is a $20B+ market with no curative therapies; deep B-cell depletion via NK cells could be transformative. Artiva raised $300M in May 2024, with $349.4M cash as of June 2026, funding operations into 2029. At $340M market cap, ARTV offers binary upside on Phase 3 initiation and interim data readouts. Screens met: 1 (valuation below biotech peers with similar catalysts), 2 (path to FCF if Phase 3 succeeds), 6 (Phase 3 initiation H2 2026, interim data H1 2027), 7 (institutional ownership rising post-funding).
KOD
Thesis: Kodiak Sciences reported positive topline Phase 3 DAYBREAK results for Zenkuda (KSI-501) in wet AMD on September 28, 2026, meeting primary endpoints (54% of patients achieved 6-month dosing interval). The stock surged 50%+ pre-market to ~$51, pushing market cap to $2.03B. Zenkuda could reduce treatment burden vs. existing anti-VEGF therapies (Eylea, Vabysmo), with a $5B+ TAM in wet AMD. Kodiak has no debt and $200M+ cash post-financing, funding commercialization. At $2.03B, KOD trades at ~10x EV/sales if Zenkuda achieves $200M peak sales (conservative). Screens met: 1 (valuation below peers with approved assets), 2 (revenue inflection from $0 to commercial sales), 6 (BLA submission Q4 2026, approval H2 2027).
TYGO
Thesis: Tigo Energy provides module-level power electronics (MLPE) for solar installations, with rapid shutdown and monitoring solutions. The company is benefiting from the U.S. Inflation Reduction Act (IRA) tailwinds and NEC 2023 rapid shutdown requirements. Revenue grew 247% YTD in 2026, with gross margins improving to 35%+. At $374M market cap, TYGO trades at ~8x EV/sales on an annualized $50M+ revenue base, leaving room for 3x–5x upside if solar installations sustain growth. Screens met: 1 (P/S below industry median for solar tech), 3 (247% YTD growth, IRA tailwinds), 6 (NEC 2023 compliance driving MLPE adoption).
Other models on the same run
| Model | Picks |
|---|---|
| Gemini 1.5 Pro | MGNI, IONQ, RXRX, LUNR, ACHR |
| Claude Opus 5.5 | CAPR, EOSE, QMCO, KOD, ETON |
| DeepSeek | ECX, NTWK, AKAM, SRRK, ELVA |
| Muse Spark 1.1 | EXTR, TLS, EVLV, SOUN, BBAI |
| Grok 4 | CAPR, INOD, SOUN, ACHR, RCAT |
| GPT-6 | BKSY, AMPX, ENVX, RCAT, LUNR |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.